TY  - JOUR

T1  - Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

JO  - PharmacoEconomics

UR  - http://eprints.whiterose.ac.uk/117002/

PY  - 2017/11/01

AU  - Bermejo I

AU  - Stevenson M

AU  - Archer R

AU  - Stevens JW

AU  - Goka E

AU  - Clowes M

AU  - Scott DL

AU  - Young A

ED  - 

DO  - DOI: 10.1007/s40273-017-0521-5

PB  - Adis

VL  - 35

IS  - 11

SP  - 1141

EP  - 1151

Y2  - 2024/10/19

ER  -